دورية أكاديمية
Biosimilars in India; current status and future perspectives
العنوان: | Biosimilars in India; current status and future perspectives |
---|---|
المؤلفون: | Bikash R Meher, Sakthi Balan, Rashmi R Mohanty, Monalisa Jena, Smita Das |
المصدر: | Journal of Pharmacy and Bioallied Sciences, Vol 11, Iss 1, Pp 12-15 (2019) |
بيانات النشر: | Wolters Kluwer Medknow Publications, 2019. |
سنة النشر: | 2019 |
المجموعة: | LCC:Pharmacy and materia medica LCC:Analytical chemistry |
مصطلحات موضوعية: | Biosimilars, European Medicines Agency, Food and Drug Administration, similar biologics, Pharmacy and materia medica, RS1-441, Analytical chemistry, QD71-142 |
الوصف: | Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in early 2000. India is one of the leading manufacturers of similar biologics. India has developed a new guideline in 2012 for the pre- and post-marketing approval of similar biologics. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 0975-7406 |
Relation: | http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2019;volume=11;issue=1;spage=12;epage=15;aulast=Meher; https://doaj.org/toc/0975-7406 |
DOI: | 10.4103/JPBS.JPBS_167_18 |
URL الوصول: | https://doaj.org/article/b43038cbbb4a41a29b9d1e5c5196c58a |
رقم الأكسشن: | edsdoj.b43038cbbb4a41a29b9d1e5c5196c58a |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 09757406 |
---|---|
DOI: | 10.4103/JPBS.JPBS_167_18 |